Ferring Pharmaceuticals today announced an agreement that will expand its Women’s Health product portfolio with the acquisition of the global rights to Xanodyne Pharmaceutical’s LYSTEDA™…

Healthcare professionals need to consider the impact of prostate cancer on the ‘whole man’ rather than focusing on cancer treatment in isolation, according to results from an international survey of prostate cancer patients and their partners…

Study results discussed today at the European Association of Urology (EAU) Congress in Barcelona, have reinforced the association between nocturia and a greater risk of falls and mortality…

Xanodyne Pharmaceuticals, Inc., an integrated specialty pharmaceutical company with both development and commercial capabilities focused on women’s healthcare and pain management…

Results from a phase III pivotal study sub-analyses reported in European Urology show that…

Frederik Paulsen, Chairman, Ferring Pharmaceuticals, announced a $3 million donation to the Royal Textile Academy of Bhutan…

Ferring Pharmaceuticals is proud to announce the second Ferring Research Infertility and Gynaecology GrAnt (FRIGGA) today…

New data from an economic analysis presented today at this year’s European Society of Human Reproduction and Embryology (ESHRE) congress showed that…

Ferring is proud to announce the launch of its first Fertility Media Award (FIMA) today during the 25th Annual Society of Human Reproduction and Embryology (ESHRE) congress…

Ferring Pharmaceuticals announced today that Dr. John Patterson CBE FRCP has been appointed as a new Board Member with immediate effect…